Results 51 to 60 of about 66,709 (255)

Splenectomy does not affect the development of pneumonia following severe traumatic brain injury

open access: yesBrain, Behavior, & Immunity - Health, 2020
The cholinergic anti-inflammatory pathway offers a proposed mechanism to describe the increased risk of pneumonia following severe traumatic brain injury (sTBI).
Rindi Uhlich   +4 more
doaj   +1 more source

Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura : A Single Technology Appraisal [PDF]

open access: yes, 2008
Evidence Review Group (ERG) final report for the National Institute for Health and Clinical ExcellencePublisher ...
Boyers, Dwayne   +5 more
core  

Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In a single‐center cohort of 577 adult LDLT recipients who underwent simultaneous splenectomy, clinically significant SFSS grade B/C (ILTS‐iLDLT‐LTSI 2023) occurred in 18.2% and was associated with inferior graft survival. Multivariate analysis identified MELD ≥ 30, NLR ≥ 4.5, and donor age ≥ 50 years as independent risk factors, which risk rising ...
Kyohei Yugawa   +6 more
wiley   +1 more source

TyG index and insulin resistance in beta-thalassemia [PDF]

open access: yes, 2015
Insulin resistance (IR) underlies some glucose metabolism abnormalities in thalassemia major. Recently, triglyceride glucose index (TyG) has been proposed for evaluating insulin resistance as a simple, low cost, and accessible tool.
Fayaz, M.   +3 more
core   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata   +4 more
wiley   +1 more source

The role of adrenocortical steroids in reversing established homograft rejection [PDF]

open access: yes, 1964
Renal homotransplantation was performed in 8 dogs. Antirejection therapy with azathioprine (BW 57-322, Imuran) was given in doses of 2 to 7.5 mg. per kilogram per day.
Axtell, HK   +4 more
core  

The impact of splenectomy on outcomes after distal and total pancreatectomy

open access: yesWorld Journal of Surgical Oncology, 2007
Background Several authors advocate spleen preserving distal pancreatectomy, because of the increased complication rate after splenectomy. Methods Postoperative complications and survival after distal and total pancreatectomy, were recorded and ...
Bramhall Simon   +5 more
doaj   +1 more source

Laparoscopy in liver transplantation: The future has arrived [PDF]

open access: yes, 2012
In the last two decades, laparoscopy has revolutionized the field of surgery. Many procedures previously performed with an open access are now routinely carried out with the laparoscopic approach.
Berloco, Pasquale Bartolomeo   +9 more
core   +2 more sources

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo   +38 more
wiley   +1 more source

Home - About - Disclaimer - Privacy